The Use of Natural Agents to Counteract Telomere Shortening: Effects of a Multi-Component Extract of Astragalus mongholicus Bunge and Danazol
article
OA: gold
CC0
AI-generated summary
A multi-component extract of Astragalus mongholicus Bunge significantly elongated telomeres in peripheral blood lymphocytes from healthy donors, demonstrating less toxicity than danazol and suggesting potential for managing age-related diseases.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Bunge and assessed its effects on telomeres compared to those of danazol. Astragalosides I to IV, flavonoids, amino acids and sugars were detected in the HRE. Samples of peripheral blood lymphocytes with short telomeres from 18 healthy donors (mean age 63.5 years; range 3286 years) were exposed to a single dose of 1 µg/mL HRE or danazol for three days. Telomere length and telomerase expression were then measured. Significant elongation of telomeres associated to a less toxicity was observed in lymphocytes from 13/18 donors following HRE treatment (0.54 kb (0.15-2.06 kb)) and in those from 9/18 donors after danazol treatment (0.95 kb (0.06-2.06 kb)). The rate of cells with short telomeres (<3 kb) decreased in lymphocytes from all donors after exposure to either HRE or danazol, telomere elongation being telomerase-dependent. These findings suggest that the HRE could be used for the management of age-related diseases.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (52)
- Danazol Treatment for Telomere Diseases via openalex
- doi:10.1038/nrg1656 via openalex
- doi:10.1158/0008-5472.can-09-4357 via openalex
- doi:10.1016/j.celrep.2012.08.023 via openalex
- doi:10.1016/j.ceb.2012.09.004 via openalex
- doi:10.1093/rpd/ncu296 via openalex
- doi:10.1182/blood-2014-08-594176 via openalex
- doi:10.3390/molecules191118850 via openalex
- doi:10.1038/nrc3025 via openalex
- doi:10.1093/nar/gkv714 via openalex
- doi:10.1182/blood.v53.3.504.504 via openalex
- doi:10.1089/dna.2009.0932 via openalex
- doi:10.3390/cells2010057 via openalex
- doi:10.1016/j.ijrobp.2014.01.021 via openalex
- doi:10.1038/ncomms1708 via openalex
- doi:10.1093/ije/dyp273 via openalex
- doi:10.1073/pnas.0407162101 via openalex
- doi:10.1039/c5ra04291g via openalex
- W2418535352 via openalex
- W2483213177 via openalex
- doi:10.1089/rej.2015.1793 via openalex
- doi:10.14336/ad.2015.1004 via openalex
- doi:10.3324/haematol.2015.129239 via openalex
- doi:10.1002/ptr.5188 via openalex
- doi:10.14336/ad.2016.0312 via openalex
- doi:10.3390/cancers10060169 via openalex
- doi:10.18632/oncotarget.15592 via openalex
- doi:10.4268/cjcmm20160526 via openalex
- doi:10.14336/ad.2018.1026 via openalex
- doi:10.12688/f1000research.14068.1 via openalex
- doi:10.1016/j.mad.2017.04.004 via openalex
- doi:10.3390/cancers10070233 via openalex
- doi:10.1159/000447841 via openalex
- doi:10.1083/jcb.201610111 via openalex
- W6754652247 via openalex
- doi:10.3892/etm.2018.6501 via openalex
- doi:10.1073/pnas.1902452116 via openalex
- doi:10.1111/resp.13456 via openalex
- doi:10.14336/ad.2017.0103 via openalex
- doi:10.14336/ad.2017.0130 via openalex
- doi:10.3390/genes7070039 via openalex
- doi:10.1089/rej.2010.1085 via openalex
- doi:10.1182/blood-2008-09-178871 via openalex
- doi:10.14336/ad.2016.0620 via openalex
- doi:10.1016/j.ijrobp.2007.01.050 via openalex
- doi:10.1016/j.jchromb.2013.11.017 via openalex
- doi:10.1038/s41598-018-35043-w via openalex
- doi:10.1080/10428194.2018.1482544 via openalex
- doi:10.1111/j.1474-9726.2011.00700.x via openalex
- doi:10.4172/2167-0412.1000230 via openalex
- doi:10.1182/bloodadvances.2018016964 via openalex
- doi:10.14336/ad.2017.0816 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T03:15:54.723740+00:00
License: CC0
· commercial use OK